Single-sided Deafness and Cochlear Implantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Cochlear implant (CI) technology has been widely used for individuals with bilateral sensorineural hearing loss to improve the ability to perceive sound by bypassing the damaged portion of the inner ear. Recently in the U.S., Cochlear implantation has also been approved by the FDA for treatment of single-sided deafness. By restoring binaural hearing, cochlear implantation in unilateral hearing loss may improve hearing in noise and sound localization, however its audiologic outcomes and quality of life impact for patients remain incompletely understood.
This study aims to establish a prospective database to track and quantify the change in general health status, tinnitus severity, spatial hearing ability, and difficulty with communication in noise after unilateral cochlear implantation in patients with SSD undergoing routine medical and audiologic evaluation at the Johns Hopkins Cochlear Implant Center. Study participants will complete survey questionnaires and undergo standard-of-care audiological evaluation before and after cochlear implantation. Data collected in this study will be invaluable in gaining an in-depth understanding of the effects of cochlear implantation in patients with SSD in the context of current FDA guidelines, and lead to better counseling and patient selection for this treatment modality.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jalisa Bass, BS
- Phone Number: 410-614-9825
- Email: jbass14@jhu.edu
Study Contact Backup
- Name: Theresa Rogers
- Phone Number: 410-955-7083
- Email: sbowdit@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Outpatient Center
-
Bethesda, Maryland, United States, 20814
- Johns Hopkins Suburban
-
Lutherville-Timonium, Maryland, United States, 21093
- Johns Hopkins Greenspring Station
-
Nottingham, Maryland, United States, 21236
- Johns Hopkins White Marsh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- For individuals ages 18 years-old and above, limited benefit from unilateral amplification is defined by test scores of 5% correct or less on monosyllabic consonant-nucleus-consonant (CNC) words in quiet when tested in the ear to be implanted alone.
- Before implantation with a cochlear implant, individuals with SSD or AHL must have at least 1-month experience wearing a Contra Lateral Routing of Signal (CROS) hearing aid or other relevant device and not show any subjective benefit.
- Medical and surgical clearance for cochlear implantation.
Exclusion Criteria:
- Not meeting FDA candidacy criteria for cochlear implantation in SSD
- Inability to perform audiologic tasks (e.g. non-English speaking)
- Medical or surgical contraindication to general anesthesia or cochlear implant surgery
- Does not wish to participate
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cochlear implant recipients
Patients with single-sided deafness undergoing cochlear implantation
|
Patients who receive cochlear implant for single-sided deafness
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Speech recognition in quiet
Time Frame: Baseline and up to 1 year post-implantation
|
Change in Speech recognition in quiet will be assessed using the percent correct on Consonant-Noun-Consonant words and phonemes.
|
Baseline and up to 1 year post-implantation
|
|
Change in Speech recognition in noise
Time Frame: Baseline and up to 1 year post-implantation
|
Change in Speech recognition in noise will be assessed using the percent correct on AzBio with multitalker babble at 8dB signal-to-noise ratio.
|
Baseline and up to 1 year post-implantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Spatial hearing as assessed by the Spatial Hearing Questionnaire
Time Frame: Baseline and up to 1 year post-implantation
|
Score on Spatial Hearing Questionnaire.
Range: 0-100.
Higher score signifies less handicap related to sound localization.
|
Baseline and up to 1 year post-implantation
|
|
Change in Tinnitus handicap as assessed by the Tinnitus Handicap Inventory
Time Frame: Baseline and up to 1 year post-implantation
|
Score on Tinnitus Handicap Inventory.
Range: 0-100.
Higher score signifies more handicap due to tinnitus.
|
Baseline and up to 1 year post-implantation
|
|
Change in Hearing aid benefit as assessed by the Abbreviated Profile of Hearing Aid Benefit
Time Frame: Baseline and up to 1 year post-implantation
|
Score on Abbreviated Profile of Hearing Aid Benefit.
Range: 0-100.
Higher score signifies more frequent problems with hearing.
|
Baseline and up to 1 year post-implantation
|
|
Change in Health utility as assessed by the Health Utility Index
Time Frame: Baseline and up to 1 year post-implantation
|
Score on Health Utility Index.
Range: 0-1.0.
Lower score signifies lower health utility.
|
Baseline and up to 1 year post-implantation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Daniel Sun, MD, JHU
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00230644
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.